肺气肿范围对特发性肺纤维化患者系列肺功能的影响
本项事后分析汇总两项IFN-γ-1b III期随机双盲安慰剂对照试验数据,评估基线肺气肿范围与纤维化范围及48周肺功能变化的关系。肺气肿见于38%患者,纤维化与肺气肿范围呈负相关(r=-0.232;P<0.001)。肺气肿范围最大四分位组(28-65%)48周FVC下降最小,较无肺气肿组差异3.32%(P=0.047);肺气肿范围≥15%与48周FVC下降显著减少相关,但DLCO或复合生理指数无此关联。
要点
- 特发性肺纤维化合并肺气肿患者FVC下降幅度更小,可能低估疾病进展。
- 肺气肿范围≥15%时FVC下降显著减少,DLCO和复合生理指数无此关联。
- FVC可能不适用于监测肺气肿范围≥15%的IPF患者疾病进展。
核心结论
- FVC测量可能不适用于监测肺气肿范围≥15%的特发性肺纤维化患者的疾病进展。
研究设计与样本
- 事后分析汇总两项IFN-γ-1b治疗特发性肺纤维化的III期随机双盲安慰剂对照试验(GIPF-001和GIPF-007)数据。
- 纳入有48周数据、基线高分辨率CT图像且FEV1/FVC比值<0.8或>0.9(GIPF-007中<0.7或>0.9)的患者,以及随机选取比值0.8-0.9和0.7-0.8的患者。
主要发现
- 38%的患者发现肺气肿。
- 纤维化范围与肺气肿范围呈负相关(r=-0.232;P<0.001)。
- 肺气肿范围最大四分位组(28-65%)48周FVC下降最小,较无肺气肿组差异3.32%(P=0.047)。
- 多变量分析中,肺气肿范围≥15%与48周FVC下降显著减少相关(相比无肺气肿或肺气肿<15%)。
- DLCO或复合生理指数未观察到类似关联。
关键数值与推荐
- 肺气肿范围≥15%与48周FVC下降显著减少相关。
- 肺气肿范围最大四分位组(28-65%)较无肺气肿组48周FVC下降差异3.32%(P=0.047)。
临床怎么用
- 对特发性肺纤维化合并肺气肿范围≥15%的患者,FVC变化可能不能准确反映疾病进展。
- 临床监测此类患者疾病进展时需结合影像学等其他指标综合评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
RATIONALE: Patients with idiopathic pulmonary fibrosis and emphysema may have artificially preserved lung volumes. OBJECTIVES: In this post hoc analysis, we investigated the relationship between baseline emphysema and fibrosis extents, as well as pulmonary function changes, over 48 weeks. METHODS: Data were pooled from two phase III, randomized, double-blind, placebo-controlled trials of IFN-γ-1b in idiopathic pulmonary fibrosis (GIPF-001 [NCT00047645] and GIPF-007 [NCT00075998]). Patients with Week 48 data, baseline high-resolution computed tomographic images, and FEV1/FVC ratios less than 0.8 or greater than 0.9 (<0.7 or >0.9 in GIPF-007), as well as randomly selected patients with ratios of 0.8-0.9 and 0.7-0.8, were included. Changes from baseline in pulmonary function at Week 48 were analyzed by emphysema extent. The relationship between emphysema and fibrosis extents and change in pulmonary function was assessed using multivariate linear regression. MEASUREMENTS AND MAIN RESULTS: Emphysema was identified in 38% of patients. A negative correlation was observed between fibrosis and emphysema extents (r = -0.232; P < 0.001). In quartile analysis, patients with the greatest emphysema extent (28 to 65%) showed the smallest FVC decline, with a difference of 3.32% at Week 48 versus patients with no emphysema (P = 0.047). In multivariate analyses, emphysema extent greater than or equal to 15% was associated with significantly reduced FVC decline over 48 weeks versus no emphysema or emphysema less than 15%. No such association was observed for diffusing capacity of the lung for carbon monoxide or composite physiologic index. CONCLUSIONS: FVC measurements may not be appropriate for monitoring disease progression in patients with idiopathic pulmonary fibrosis and emphysema extent greater than or equal to 15%.
引用
- Cottin V, Hansell DM, Sverzellati N, et al. Effect of Emphysema Extent on Serial Lung Function in Patients with Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med. 2017. PMID: 28657784. doi:10.1164/rccm.201612-2492OC
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。